摘要
目的观察恩替卡韦对乙型肝炎肝功能衰竭患者的疗效与安全性。方法选择2012年1月至2014年12月于本院住院的乙型肝炎肝功能衰竭患者56例,采用随机数字表法分为治疗组和对照组,各28例。治疗组在常规治疗基础上予以恩替卡韦0.5 mg/d,口服。对照组仅给予综合对症支持治疗。观察两组患者48周后的生存率、肝功能变化、PTA和HBV DNA低于检测下限的比率,比较治疗组与对照组的疗效。结果治疗组与对照组治疗48周生存率分别为71.4%和42.9%,治疗组生存率高于对照组（χ2=4.67,P=0.031）。治疗48周后,治疗组的PTA和TBil分别为（73±10）%和（55±13）μmol/L,对照组的PTA和TBil分别为（61±10）%和（89±22）μmol/L,差异均有统计学意义（t=0.003、-11.44,P=0.031、0.000）。治疗组HBV DNA低于检测下限的比率为80.0%,对照组为41.7%,差异有统计学意义（χ2=4.89,P=0.027）。结论恩替卡韦可提高乙型肝炎肝功能衰竭患者的生存率,能够改善肝功能且安全性较好。
Objective To observe the therapeutic effects and its safety of entecavir in treatment of hepatitis B patients with liver failure. Methods Total of 56 hepatitis B patients with liver failure from January 2014 to December 2014 in Third Peoples＇ Hospital of Jiujiang were selected and randomly divided into treatment group and control group, 28 cases in each group. The treatment group were treated with entecavir 0.5 mg/d orally on the basis of basic supportive therapy. The control group were only given basic medical therapy. The survival rate, liver function, prothrombin activity（PTA） and negative rate of HBV DNA at 48 weeks after treatment were observed and compared. Results The survival rate of treatment group and control group were 71.4% and 42.9%, respectively, and the difference was statistically significant（χ2 = 4.67, P = 0.031）. After 48 weeks＇ treatment, the levels of PTA and TBil in treatment group were（73 ± 10）% and（55 ± 13） μmol/L, which in control group were（61 ± 10）% and（89 ± 22） μmol/L, respectively, the differences were statistically significant（t = 0.003,-11.44; P = 0.031, 0.000）. The negative rate of HBV DNA in treatment group and control group were 80.0% and 41.7%, respectively, the difference was statistically significant（χ2 = 4.89, P = 0.027）. Conclusion Entecavir is safe and can improve the survival rate and liver function in hepatitis B patients with liver failure.
出处
《中国肝脏病杂志（电子版）》
CAS
2016年第2期120-122,共3页
Chinese Journal of Liver Diseases：Electronic Version
作者简介
通讯作者：高素香Email：gaosuxianggsx@sina．com
